aminocaproic acid has been researched along with Venous Thrombosis in 11 studies
Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.
Venous Thrombosis: The formation or presence of a blood clot (THROMBUS) within a vein.
| Excerpt | Relevance | Reference |
|---|---|---|
| "epsilon-Aminocaproic acid (EACA) is an antifibrinolytic agent used to prevent rebleeding in aneurysmal subarachnoid hemorrhage." | 3.74 | Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage. ( Chwajol, M; Connolly, ES; Ducruet, AF; Fernandez, A; Hahn, DK; Hickman, ZL; Kellner, CP; Kim, GH; Komotar, RJ; Mayer, SA; Otten, ML; Starke, RM, 2008) |
| "Sixty-nine adults with malignancy scheduled for either pelvic, extremity or spine surgery during general anesthesia entered this randomized, double-blind, placebo-controlled trial, and received either intravenous aprotinin (n = 23), bolus of 2 x 10(6) kallikrein inactivator units (KIU), followed by an infusion of 5 x 10(5) KIU/h, or EACA (n = 22), bolus of 150 mg/kg, followed by a 15 mg/kg/h infusion or saline placebo (n = 24) during surgery." | 2.71 | Antifibrinolytic therapy and perioperative blood loss in cancer patients undergoing major orthopedic surgery. ( Amar, D; Boland, PJ; Grant, FM; Healey, JA; Leung, DH; Zhang, H, 2003) |
| " Secondary outcomes were other adverse events, blood transfusion, and blood loss." | 2.55 | The Safety and Efficacy of Lysine Analogues in Cancer Patients: A Systematic Review and Meta-Analysis. ( Breau, RH; Cagiannos, I; Cnossen, S; Fergusson, DA; Fergusson, NA; Hutton, B; Lavallée, LT; Montroy, J; Morash, C, 2017) |
| " Deep vein thrombosis (DVT) can lead to pulmonary embolism (PE), but the mechanisms responsible for this progression are unknown." | 1.51 | Factor XIII Prevents Pulmonary Emboli in Mice by Stabilizing Deep Vein Thrombi. ( Gani, DM; Gross, PL; Kim, PY; Shaya, SA; Weitz, JI, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Zheng, C | 1 |
| Ma, J | 1 |
| Xu, J | 1 |
| Li, M | 1 |
| Wu, L | 1 |
| Wu, Y | 1 |
| Liu, Y | 1 |
| Shen, B | 1 |
| Montroy, J | 1 |
| Fergusson, NA | 1 |
| Hutton, B | 1 |
| Lavallée, LT | 1 |
| Morash, C | 1 |
| Cagiannos, I | 1 |
| Cnossen, S | 1 |
| Fergusson, DA | 1 |
| Breau, RH | 1 |
| Liu, Q | 1 |
| Geng, P | 1 |
| Shi, L | 1 |
| Wang, Q | 1 |
| Wang, P | 1 |
| Raveh, Y | 1 |
| Shatz, V | 1 |
| Lindsay, M | 1 |
| Nicolau-Raducu, R | 1 |
| Shaya, SA | 1 |
| Gani, DM | 1 |
| Weitz, JI | 1 |
| Kim, PY | 1 |
| Gross, PL | 1 |
| Foreman, PM | 1 |
| Chua, M | 1 |
| Harrigan, MR | 1 |
| Fisher, WS | 1 |
| Tubbs, RS | 1 |
| Shoja, MM | 1 |
| Griessenauer, CJ | 1 |
| Starke, RM | 1 |
| Kim, GH | 1 |
| Fernandez, A | 1 |
| Komotar, RJ | 1 |
| Hickman, ZL | 1 |
| Otten, ML | 1 |
| Ducruet, AF | 1 |
| Kellner, CP | 1 |
| Hahn, DK | 1 |
| Chwajol, M | 1 |
| Mayer, SA | 1 |
| Connolly, ES | 1 |
| Amar, D | 1 |
| Grant, FM | 1 |
| Zhang, H | 1 |
| Boland, PJ | 1 |
| Leung, DH | 1 |
| Healey, JA | 1 |
| HALLER, JA | 1 |
| MAYS, T | 1 |
| NORDOEY, A | 1 |
| Molenaar, IQ | 1 |
| Warnaar, N | 1 |
| Groen, H | 1 |
| Tenvergert, EM | 1 |
| Slooff, MJ | 1 |
| Porte, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss, Transfusion Index and Complications After Total Hip Replacement. A Prospective, Randomized, Double Blind Clinical Trial[NCT04187014] | Phase 2 | 90 participants (Actual) | Interventional | 2020-02-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for aminocaproic acid and Venous Thrombosis
| Article | Year |
|---|---|
The Optimal Dose, Efficacy and Safety of Tranexamic Acid and Epsilon-Aminocaproic Acid to Reduce Bleeding in TKA: A Systematic Review and Bayesian Network Meta-analysis.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2023 |
The Safety and Efficacy of Lysine Analogues in Cancer Patients: A Systematic Review and Meta-Analysis.
Topics: Adult; Aminocaproic Acid; Blood Loss, Surgical; Blood Transfusion; Erythrocyte Transfusion; Humans; | 2017 |
Tranexamic acid versus aminocaproic acid for blood management after total knee and total hip arthroplasty: A systematic review and meta-analysis.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Repl | 2018 |
Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Controlled Cl | 2007 |
1 trial available for aminocaproic acid and Venous Thrombosis
| Article | Year |
|---|---|
Antifibrinolytic therapy and perioperative blood loss in cancer patients undergoing major orthopedic surgery.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Cell Count; Blood Loss, Surgical; | 2003 |
6 other studies available for aminocaproic acid and Venous Thrombosis
| Article | Year |
|---|---|
Disseminated intravascular coagulation during liver transplantation unleashed by protamine.
Topics: Aged; Aminocaproic Acid; Blood Loss, Surgical; Carcinoma, Hepatocellular; Disseminated Intravascular | 2019 |
Factor XIII Prevents Pulmonary Emboli in Mice by Stabilizing Deep Vein Thrombi.
Topics: Aminocaproic Acid; Animals; Anticoagulants; Antifibrinolytic Agents; Blood Platelets; Cells, Culture | 2019 |
Antifibrinolytic therapy in aneurysmal subarachnoid hemorrhage increases the risk for deep venous thrombosis: A case-control study.
Topics: Adult; Aged; Aminocaproic Acid; Aneurysm, Ruptured; Angiography, Digital Subtraction; Antifibrinolyt | 2015 |
Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage.
Topics: Acute Disease; Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Clinical Protocols; Drug Adm | 2008 |
EXPERIMENTAL STUDIES ON ILIOFEMORAL VENOUS THROMBOSIS.
Topics: Aminocaproates; Aminocaproic Acid; Animals; Dogs; Femoral Vein; Fibrinolysis; Iliac Vein; Lymphedema | 1963 |
EXPERIMENTAL VENOUS THROMBOSIS IN RATS. INCREASED FORMATION DURING INHIBITION OF THE FIBRINOLYTIC SYSTEM WITH EPSILON AMINO CAPROIC ACID.
Topics: Aminocaproates; Aminocaproic Acid; Caproates; Fibrinolysis; Rats; Research; Thrombophlebitis; Thromb | 1963 |